Circulatory system mortality declining in Hodgkin's

March 9, 2013
Circulatory system mortality declining in hodgkin's
Among patients treated for Hodgkin's lymphoma, long-term excess mortality due to diseases of the circulatory system is expected to continue to decline, according to research published online Feb. 25 in the Journal of Clinical Oncology.

(HealthDay)—Among patients treated for Hodgkin's lymphoma (HL), long-term excess mortality due to diseases of the circulatory system (DCS) is expected to continue to decline, according to research published online Feb. 25 in the Journal of Clinical Oncology.

In an effort to estimate the treatment-related mortality caused by DCS, Sandra Eloranta, of the Karolinska Institute in Stockholm, and colleagues used population-based data for 5,462 patients diagnosed with and treated for HL between 1973 and 2006.

The researchers note that, since the mid-1980s, DCS mortality in HL patients has steadily declined. Patients who were older when diagnosed and men were at higher risk of death due to DCS. After accounting for other causes of death, the number of deaths attributed to HL treatment-related DCS was actually only a small proportion.

"This study shows how the long-term excess DCS mortality experienced by patients with HL in Sweden, diagnosed and treated in the 1990s and early 2000s, is expected to further decrease compared with that of patients diagnosed in earlier years. A similar, but stronger, trend is also observed for the remaining excess HL mortality," the authors write. "The improvements in survival are not likely to be explained by changes in disease characteristics (i.e., a more favorable distribution of in recent years)."

Explore further: HIV status doesn't influence Hodgkin's lymphoma outcome

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

HIV status doesn't influence Hodgkin's lymphoma outcome

October 11, 2012

(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, and dacarbazine ...

Bone marrow biopsy adds little to PET/CT staging of Hodgkin's

November 15, 2012

(HealthDay)—For patients with treatment-naive Hodgkin's lymphoma (HL) staged using [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), routine bone marrow biopsy (BMB) has little or no therapeutic ...

Alkylating agent linked to therapy-related leukemia

January 15, 2013

(HealthDay)—For patients treated for Hodgkin's lymphoma (HL), cumulative doses of alkylating agent (AA) is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS), according ...

Ulcerative colitis, not crohn's, deaths down from 1982

January 21, 2013

(HealthDay)—Over the past 30 years in Denmark, mortality from ulcerative colitis (UC) has decreased, but mortality from Crohn's disease (CD) has remained persistently higher than the general population, according to research ...

Predictors of mortality, CVD risk in cushing's disease ID'd

March 1, 2013

(HealthDay)—A number of factors, including the duration of glucocorticoid exposure, older age at diagnosis, and preoperative adrenocorticotropic hormone (ACTH) concentration, are associated with a higher risk of mortality ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.